Sinofn Health
Sinofn Health
In the rapidly evolving landscape of functional ingredients, Kava (Piper methysticum) has emerged as a premier botanical for anxiety management and cognitive relaxation. However, traditional ingestion methods face significant barriers: poor water solubility and degradation in the gastric environment. SINOFN Health has revolutionized this via our Quantum Kava Liposomal Technology.
By utilizing advanced liposomal encapsulation, we protect the bioactive kavalactones from premature metabolic breakdown. This "Quantum" approach—referring to the sub-micron scale precision of our lipid bilayer carriers—ensures that the active compounds achieve superior bioavailability. For global supplement brands, this means products that work faster, require lower dosages for efficacy, and offer a premium user experience. We are not just a manufacturer; we are a scientific partner.
The global procurement trend is pivoting sharply towards efficacy-focused formulations. Brands no longer seek generic botanical extracts; they demand documented bioavailability profiles. The market for liposomal-enhanced supplements is projected to grow at a CAGR of 12% through 2030. Key procurement drivers include:
SINOFN provides a comprehensive macro-solution that bridges the gap between raw botanical sourcing and shelf-ready retail products. Navigating the regulatory landscape for Kava can be complex due to varying regional restrictions. Our team provides:
SINOFN Health Co., Ltd. is the dedicated supplement OEM manufacturing division of SINOFN Group — a national high-tech enterprise founded in 2012 and backed by the Chinese Academy of Sciences. Established in 2025, we operate from Shanghai as the trading hub for global partners seeking premium, science-driven contract manufacturing services.
During her clinical work, Mrs. GuoHong Liu witnessed lifelong struggles of PKU (Phenylketonuria) children — where specialized diets were financially out of reach. Driven to bridge this gap, she founded SINOFN in 2012. Today, this mission for "accessible science" dictates our high-quality production standards across all product lines, including our advanced Kava formulations.
Our team is led by Dr. Zhang Ying (Chinese Academy of Sciences Postdoc) and Dr. Tan Shengjie (Peking University Medical Doctor), with Mr. Hans (Netherlands) serving as chief engineer for industrialization. We integrate advanced clinical knowledge into every batch we manufacture, ensuring that our clients receive products that are not only market-competitive but scientifically validated.
Looking ahead, SINOFN is investing heavily in "AI-Driven Formulation Development." By leveraging data from bioavailability studies and consumer feedback loops, our R&D team can predict formulation stability and consumer uptake more accurately than ever before. We are expanding our Kava liposome capabilities to include sustained-release delivery systems, set to redefine the nocturnal sleep aid market.
We operate state-of-the-art facilities in China, strategically positioned with global shipping hubs in Shanghai to serve international markets efficiently. Our facilities are ISO22000, HACCP, and FSSC 22000 certified.
Yes. We specialize in pilot runs, providing full-scale prototyping for tablets, capsules, and liquids to test market viability before mass production.
Absolutely. We offer tailored manufacturing scopes that allow startups to scale gracefully while supporting enterprise-level brands with annual capacities exceeding 500 million units.
With 36 registered patents and a focus on contract manufacturing, we maintain strict intellectual property protocols to ensure your custom formulations remain exclusively yours.
